1453167-99-1

Basic information

• Product Name: ent-14S-3-Methoxy-17-MethylMorphinan
• Synonyms: ent-14S-3-Methoxy-17-MethylMorphinan;Morphinan, 3-Methoxy-17-Methyl-, (9a,13a)-;Dextromethorphan EP Impurity D;(4bS,8aR,9S)-3-methoxy-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene
• CAS NO: 1453167-99-1
• Molecular Formula: C18H25NO
• Molecular Weight: 271.3972
• Mol File: 1453167-99-1.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 394.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• PKA: 9.13±0.20(Predicted)
• CAS DataBase Reference: ent-14S-3-Methoxy-17-MethylMorphinan(CAS DataBase Reference)
• NIST Chemistry Reference: ent-14S-3-Methoxy-17-MethylMorphinan(1453167-99-1)
• EPA Substance Registry System: ent-14S-3-Methoxy-17-MethylMorphinan(1453167-99-1)

Safety Data

• Hazardous Substances Data: 1453167-99-1(Hazardous Substances Data)

Usage

Description

ent-14S-3-Methoxy-17-MethylMorphinan, also known as (9α,13α)-3-Methoxy-17-methylmorphinan, is an analog of Dextromethorphan (D299445), a well-known antitussive compound with demonstrated analgesic properties. ent-14S-3-Methoxy-17-MethylMorphinan is derived from the morphinan class of organic compounds, which are known for their diverse range of biological activities and potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
ent-14S-3-Methoxy-17-MethylMorphinan is used as an active pharmaceutical ingredient for its antitussive and analgesic properties. It serves as a key component in the development of cough medication formulations, providing relief from coughing and pain associated with respiratory conditions.
Used in Cough Medication Formulations:
ent-14S-3-Methoxy-17-MethylMorphinan is used as an antitussive agent for the treatment of coughs. Its effectiveness in suppressing cough reflexes makes it a valuable addition to over-the-counter and prescription cough medications, particularly for individuals suffering from persistent or severe coughs.
Used in Pain Management:
As an analog of Dextromethorphan with analgesic properties, ent-14S-3-Methoxy-17-MethylMorphinan is used in pain management applications. Its ability to alleviate pain makes it a potential candidate for the development of new pain relief medications, offering an alternative to existing treatments and potentially improving patient outcomes.

Upstream product

• 186581-53-3 diazomethane 
• 77-07-6 Levorphanol 
• 51745-06-3 N-formyl-3-methoxymorphinan 
• 3399-73-3 2-(1-cyclohexenyl)ethylamine 
• 98237-33-3 1-(4-Methoxybenzyl)-2-methyl-5,6,7,8-tetrahydroisochinoliniumiodide 
• 888939-18-2 3-Hydroxy-N-methylmorphinan 
• 38969-65-2 1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 77-07-6 racemorphan 
• 51072-36-7 (+)-1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 1899-02-1 trimethylphenylammonium hydroxide 
• 67596-84-3 (+)-2-methyl-1-(4-methoxy)benzyl-1,2,3,4,5,6,7,8-hexahydroisoquinoline 
• 6700-34-1 dextromethorphan hydrobromide, monohydrate 
• 113951-04-5 dextromethorphan N-oxide hydrochloride 
• 29144-31-8 (S)-2-Formyl-1-<(4-methoxyphenyl)methyl>-1,2,3,4,5,6,7,8-octahydroispquinoline 

Downstream Products

• 18050-88-9 3-methoxy-10-keto-N-methylmorphinan 
• 121292-34-0 ent-(17Ξ)-17-benzyl-3-methoxy-17-methyl-morphinanium; bromide 
• 57969-05-8 (9α,13α,14α)-3-methoxy-17-methylmorphinan-10-one 
• 113951-05-6 dextromethorphan N-oxide 
• 113951-05-6 rac-(17Ξ)-3-methoxy-17-methyl-morphinane-17-oxide 
• 118982-15-3 ent-17-benzyl-3-methoxy-17-methyl-9,10-didehydro-9,17-seco-morphinane 
• 524713-56-2 N-CD3-dextromethorphan 
• 1531-23-3 (4bR,9R)-3-methoxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene 
• 1079043-55-2 [2H]-Dextromethorphan 3,17-d6 
• 36304-81-1 Dimemorfan 
• 1531-23-3 3-methoxymorphinan 
• 1079043-47-2 (4bS,8aS,9S)-ethyl 3-hydroxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate 
• 18609-21-7 Dextromethorphan hydrochloride 
• 53447-08-8 [18,18,18-2H₃]-6-hydroxy-17-methyl-morphinan 

Relevant articles and documents

METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF

A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.

DEUTERATED MORPHINAN COMPOUNDS FOR USE IN TREATING AGITATION

This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.

Contra-thermodynamic Hydrogen Atom Abstraction in the Selective C-H Functionalization of Trialkylamine N-CH3 Groups

We report a simple one-pot protocol that affords functionalization of N-CH3 groups in N-methyl-N,N-dialkylamines with high selectivity over N-CH2R or N-CHR2 groups. The radical cation DABCO+?, prepared in situ by oxidation of DABCO with a triarylaminium salt, effects highly selective and contra-thermodynamic C-H abstraction from N-CH3 groups. The intermediates that result react in situ with organometallic nucleophiles in a single pot, affording novel and highly selective homologation of N-CH3 groups. Chemoselectivity, scalability, and recyclability of reagents are demonstrated, and a mechanistic proposal is corroborated by computational and experimental results. The utility of the transformation is demonstrated in the late-stage site-selective functionalization of natural products and pharmaceuticals, allowing rapid derivatization for investigation of structure-activity relationships.